SCHEMBL878470

SCHEMBL878470

COc1ccc2c(c1)c(CC(=O)NCCCCNC(=O)c1ccc(C=O)c(-c3c4ccc(=O)cc-4oc4cc(O)ccc34)c1)c(C)n2C(=O)c1ccc(Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 12/20 0.55
PTGS1 P23219 4/20 0.55
HRH4 Q9H3N8 1/20 0.54
HDAC3 O15379 3/20 0.53
HDAC1 Q13547 3/20 0.53
HDAC8 Q9BY41 3/20 0.53
HDAC6 Q9UBN7 3/20 0.53
HDAC2 Q92769 1/20 0.53
APP P05067 1/20 0.53
BCHE P06276 1/20 0.53
ACHE P22303 1/20 0.53
CA12 O43570 3/20 0.52
CA4 P22748 3/20 0.52
CA9 Q16790 3/20 0.52
TRPV1 Q8NER1 1/20 0.51
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL861480 0.91 PTGS2 (0.56) PTGS2PTGS1HRH4HDAC3HDAC1
SCHEMBL861064 0.91 PTGS2 (0.57) PTGS2PTGS1HRH4HDAC3HDAC1
SCHEMBL860836 0.88 PTGS2 (0.58) PTGS2PTGS1HRH4HDAC3HDAC1
SCHEMBL861487 0.87 PTGS2 (0.51) PTGS2PTGS1HRH4HDAC3HDAC1
SCHEMBL14731425 0.84 PTGS2 (0.54) PTGS2PTGS1HRH4HDAC3HDAC1
SCHEMBL861474 0.83 CA12 (0.56) PTGS2PTGS1HRH4HDAC3HDAC1
SCHEMBL16181473 0.83 PTGS2 (0.53) PTGS2PTGS1HRH4HDAC3HDAC1
SCHEMBL860830 0.82 CA12 (0.55) PTGS2PTGS1HRH4APPBCHE
SCHEMBL10148093 0.81 ALB (0.49) CA12CA9CA1CA2
SCHEMBL860837 0.81 PTGS2 (0.50) PTGS2PTGS1HRH4HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143302-B2 Methods and compositions for diagnostic and therapeutic targeting of COX-2 VANDERBILT UNIVERSITY (US) 2012-03-27 US disclosed
US-20100254910-A1 METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 VANDERBILT UNIVERSITY (US) 2010-10-07 US disclosed
US-7736624-B2 derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy UNIV VANDERBILT (US) 2010-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100254910-A1 METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 PTGS2, PTGES2, PTGER2 PTGS2 1/4885PTGS1 5/4885HRH4 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.